Dacomitinib Approved: Metastatic Non-Small Cell Lung Cancer

​The FDA has approved dacomitinib tablets (Vizimpro®, Pfizer) for first-line treatment of patients with metastatic non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) exon 19 deletion or exon 21 L858R substitution mutations. Comprising approximately 85% of lung cancer cases, NSCLC is challenging to treat, especially when it has metastasized. Around 75% of NSCLC patients remain undiagnosed until they have reached a state of advanced or metastatic disease, which has a 5...
Continue reading

Subscribe

Get the latest updates delivered to your inbox!

Follow Us

Copyright © 2021 Oncology Data Advisor. All rights reserved.